| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $1,955,000 | 2026 | THE CUREALZ ALZHEIMER'S GENOME PROJECT |
| BRIGHAM AND WOMEN'S HOSPITAL | BOSTON, MA | $575,000 | 2026 | APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS |
| BRIGHAM AND WOMEN'S HOSPITAL | BOSTON, MA | $431,250 | 2026 | A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE |
| WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | NEW YORK, NY | $402,500 | 2026 | SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES |
| UNIVERSITY OF MICHIGAN | ANN ARBOR, MI | $402,500 | 2026 | NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES |
| UNIVERSITY OF CALIFORNIA IRVINE | IRVINE, CA | $402,492 | 2026 | PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE |
| UNIVERSITY OF MICHIGAN | ANN ARBOR, MI | $398,521 | 2026 | UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $345,000 | 2026 | APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $345,000 | 2026 | BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $345,000 | 2026 | BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE |
| BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $344,528 | 2026 | NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE |
| THE MCLEAN HOSPITAL CORPORATION | BELMONT, MA | $327,501 | 2026 | EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS |
| DUKE UNIVERSITY SCHOOL OF MEDICINE | DURHAM, NC | $320,033 | 2026 | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $300,000 | 2026 | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY |
| NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE | BETHESDA, MD | $287,673 | 2026 | BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS |
| NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NEW YORK, NY | $287,500 | 2026 | NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD |
| UNIVERSITY OF ROCHESTER | ROCHESTER, NY | $287,500 | 2026 | BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $287,500 | 2026 | BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $287,500 | 2026 | BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $287,500 | 2026 | NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $287,500 | 2026 | BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE |
| STANFORD UNIVERSITY | REDWOOD CITY, CA | $287,500 | 2026 | BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE |
| WASHINGTON UNIVERSITY IN ST LOUIS | ST LOUIS, MO | $287,499 | 2026 | BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE |
| UNIVERSITY OF CALIFORNIA IRVINE | IRVINE, CA | $287,490 | 2026 | NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | CAMBRIDGE, MA | $287,477 | 2026 | BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS |
| UNIVERSITY OF CALIFORNIA DAVIS | DAVIS, CA | $286,466 | 2026 | NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION |
| UNIVERSITY OF PENNSYLVANIA | PHILADELPHIA, PA | $284,678 | 2026 | APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | BIRMINGHAM, AL | $271,375 | 2026 | EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK |
| BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $264,500 | 2026 | BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT) |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $258,750 | 2026 | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT) |
| UNIVERSITY OF VIRGINIA | CHARLOTTESVILLE, VA | $258,750 | 2026 | THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT) |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $258,750 | 2026 | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT) |
| WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | NEW YORK, NY | $258,750 | 2026 | A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT) |
| GLADSTONE INSTITUTES | SAN FRANCISCO, CA | $258,615 | 2026 | DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT) |
| GLADSTONE INSTITUTES | SAN FRANCISCO, CA | $258,573 | 2026 | DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT) |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $252,076 | 2026 | MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY |
| THE BROAD INSTITUTE INC | CAMBRIDGE, MA | $230,000 | 2026 | INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS |
| PRESIDENT AND FELLOWS OF HARVARD COLLEGE | CAMBRIDGE, MA | $230,000 | 2026 | MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY |
| MAYO CLINIC JACKSONVILLE | JACKSONVILLE, FL | $230,000 | 2026 | UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $230,000 | 2026 | APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $230,000 | 2026 | ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE |
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | DALLAS, TX | $230,000 | 2026 | ENGINEERED CAR-MACROPHAGES TO CLEAR TAU |
| UNIVERSITY OF CALIFORNIA IRVINE | IRVINE, CA | $230,000 | 2026 | ENGINEERED CAR-MACROPHAGES TO CLEAR TAU |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | NEW YORK, NY | $230,000 | 2026 | INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY |
| BRIGHAM AND WOMEN'S HOSPITAL | BOSTON, MA | $228,900 | 2026 | DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? |
| NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NEW YORK, NY | $210,962 | 2026 | MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE |
| DUKE UNIVERSITY SCHOOL OF MEDICINE | DURHAM, NC | $204,656 | 2026 | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE |
| UNIVERSITY OF MICHIGAN | ANN ARBOR, MI | $201,251 | 2026 | MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD |
| AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC | AUGUSTA, GA | $201,250 | 2026 | THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY |
| UNIVERSITY OF VIRGINIA | CHARLOTTESVILLE, VA | $201,250 | 2026 | ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD |
